Search

Your search keyword '"Koca, Suleyman Serdar"' showing total 183 results
Start Over Author "Koca, Suleyman Serdar"
183 results on '"Koca, Suleyman Serdar"'

1. Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Author

Uslu, Sadettin, Gulle, Semih, Sen, Gercek, Cefle, Ayse, Yilmaz, Sema, Kocaer, Sinem Burcu, Yuce Inel, Tuba, Koca, Suleyman Serdar, Yolbas, Servet, Ozturk, Mehmet Akif, Senel, Soner, Inanc, Nevsun, Dalkilic, Huseyin Ediz, Soysal Gunduz, Ozgul, Tufan, Abdurrahman, Akar, Servet, Birlik, Ahmet Merih, Sari, Ismail, Akkoc, Nurullah, and Onen, Fatos

Published
2024
Full Text
View/download PDF

6. Extended Autoantibody Panel in Turkish Patients with Early-Stage Systemic Sclerosis: Co-expressions and Their Influences on Clinical Phenotypes

Author

Karadag, Duygu Temiz, primary, Komac, Andac, additional, Erez, Yesim, additional, Birlik, Merih, additional, Sarı, Alper, additional, Akdoğan, Ali, additional, Farisogullari, Bayram, additional, Kimyon, Gezmiş, additional, KOÇ, EMRAH, additional, TAS, DIDEM ARSLAN, additional, Karatas, Ahmet, additional, Koca, Suleyman Serdar, additional, Kasifoglu, Nilgün, additional, YAZICI, AYTEN, additional, Hayran, Kadir Mutlu, additional, and Çefle, Ayşe, additional

Published
2024
Full Text
View/download PDF

8. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry.

Author

Karaka, Ali, Gulle, Semih, Can, Gerçek, Dalkilic, Ediz, Akar, Servet, Koca, Suleyman Serdar, Pehlivan, Yavuz, Senel, Soner, Tufan, Abdurrahman, Ozturk, Mehmet Akif, Yilmaz, Sema, Yazici, Ayten, Cefle, Ayse, Inel, Tuba Yüce, Erez, Yesim, Sari, Ismail, Birlik, Merih, Direskeneli, Haner, Akkoc, Nurullah, and Onen, Fatos

Subjects
ANKYLOSING spondylitis, OBESITY, BODY mass index, BIOLOGICAL databases, SPONDYLOARTHROPATHIES
Abstract

Objectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25–30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results: There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3–33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05). Conclusions: This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).

Author

Aymon, Romain, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, De Cock, Diederik, Dreyer, Lene, Elkayam, Ori, Huschek, Doreen, Hyrich, Kimme L., Iannone, Florenzo, Inanc, Nevsun, Kearsley-Fleet, Lianne, KOCA, Suleyman Serdar, Kvien, Tore K., Leeb, Burkhard F., Lukina, Galina, Nordström, Dan C., Pavelka, Karel, and Pombo-Suarez, Manuel

Published
2024
Full Text
View/download PDF

10. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

Author

Aymon, Romain, primary, Mongin, Denis, additional, Bergstra, Sytske Anne, additional, Choquette, Denis, additional, Codreanu, Catalin, additional, De Cock, Diederik, additional, Dreyer, Lene, additional, Elkayam, Ori, additional, Huschek, Doreen, additional, Hyrich, Kimme L, additional, Iannone, Florenzo, additional, Inanc, Nevsun, additional, Kearsley-Fleet, Lianne, additional, KOCA, Suleyman Serdar, additional, Kvien, Tore K, additional, Leeb, Burkhard F, additional, Lukina, Galina, additional, Nordström, Dan C, additional, Pavelka, Karel, additional, Pombo-Suarez, Manuel, additional, Rodrigues, Ana, additional, Rotar, Ziga, additional, Strangfeld, Anja, additional, Verschueren, Patrick, additional, Westermann, Rasmus, additional, Zavada, Jakub, additional, Courvoisier, Delphine Sophie, additional, Finckh, Axel, additional, and Lauper, Kim, additional

Published
2023
Full Text
View/download PDF

11. Extended autoantibody panel in Turkish patients with early‐stage systemic sclerosis: Coexpressions and their influences on clinical phenotypes

Author

Temiz Karadağ, Duygu, primary, Komac, Andac, additional, Erez, Yesim, additional, Birlik, Ahmet Merih, additional, Sari, Alper, additional, Akdoğan, Ali, additional, Farisogullari, Bayram, additional, Kimyon, Gezmiş, additional, Koc, Emrah, additional, Arslan, Didem, additional, Karatas, Ahmet, additional, Koca, Suleyman Serdar, additional, Kasifoglu, Nilgün, additional, Yazici, Ayten, additional, Hayran, Kadir Mutlu, additional, and Cefle, Ayse, additional

Published
2023
Full Text
View/download PDF

12. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Author

Karakaş, Ali, primary, Gulle, Semih, additional, Can, Gerçek, additional, Dalkılıc, Ediz, additional, Akar, Servet, additional, Koca, Suleyman Serdar, additional, Pehlivan, Yavuz, additional, Senel, Soner, additional, Tufan, Abdurrahman, additional, Ozturk, Mehmet Akif, additional, Yilmaz, Sema, additional, Yazici, Ayten, additional, Cefle, Ayse, additional, Yüce İnel, Tuba, additional, Erez, Yesim, additional, Sari, Ismail, additional, Birlik, Merih, additional, Direskeneli, Haner, additional, Akkoc, Nurullah, additional, and Onen, Fatos, additional

Published
2023
Full Text
View/download PDF

14. The first effect of COVID-19 pandemic on starting biological disease modifying anti-rheumatic drugs: outcomes from the TReasure real-life database

Author

Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, School of Medicine, Kanıtez, Nilüfer Alpay (ORCID 0000-0003-1185-5816 & YÖK ID 239432), Kiraz, Sedat; Dalkilic, Ediz; Kimyon, Gezmis; Mercan, Ridvan; Karadag, Omer; Bes, Cemal; Kilic, Levent; Akar, Servet; Ates, Askin; Emmungil, Hakan; Ertenli, Ihsan; Pehlivan, Yavuz; Coskun, Belkis Nihan; Yagiz, Burcu; Ersozlu, Duygu; Gonullu, Emel; Cinar, Muhammet; Kasifoglu, Timucin; Koca, Suleyman Serdar; Karasu, Ugur; Kucuksahin, Orhan; Kalyoncu, Umut, and School of Medicine

Abstract

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic., NA

Published
2023

15. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Author

Akkoc, Nurullah, PEHLİVAN, YAVUZ, Senel, Soner, TUFAN, ABDURRAHMAN, ÖZTÜRK, MEHMET AKİF, SARI, İSMAİL, Yilmaz, Sema, Koca, Suleyman Serdar, Akar, Servet, Yazici, Ayten, Cefle, Ayse, DALKILIÇ, HÜSEYİN EDİZ, Inel, Tuba Yuce, Erez, Yesim, Birlik, Merih, Direskeneli, Haner, Karakas, Ali, Onen, Fatos, CAN, GÜNAY, and Gulle, Semih

Abstract

Objectives The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m(2)], overweight (BMI: 25-30 kg/m(2)), and obese (BMI & GE; 30 kg/m(2)). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 & PLUSMN; 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05). Conclusions This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.

Published
2023

17. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry

Author

Karadag, Omer, primary, Farisogullari, Bayram, additional, Yagiz, Burcu, additional, Erden, Abdulsamet, additional, Ademoglu, Zeliha, additional, Kimyon, Gezmis, additional, Bilge, Nazife Sule, additional, Icacan, Ozan Cemal, additional, Kilic, Levent, additional, Coskun, Belkis Nihan, additional, Ersozlu, Emine Duygu, additional, Kucuksahin, Orhan, additional, Mercan, Ridvan, additional, Koca, Suleyman Serdar, additional, Gonullu, Emel, additional, Cinar, Muhammet, additional, Akar, Servet, additional, Emmungil, Hakan, additional, Kasifoglu, Timucin, additional, Bes, Cemal, additional, Omma, Ahmet, additional, Pehlivan, Yavuz, additional, Kiraz, Sedat, additional, Ertenli, Ihsan, additional, Dalkilic, Ediz, additional, and Kalyoncu, Umut, additional

Published
2023
Full Text
View/download PDF

18. Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology

Author

Temiz Karadag, Duygu, primary, Yalcinkaya, Yasemin, additional, Akdogan, Ali, additional, Avanoglu, Aslihan, additional, Bes, Cemal, additional, Birlik, Ahmet Merih, additional, Cefle, Ayse, additional, Erdogan, Mustafa, additional, Hatemi, Gulen, additional, Icacan, Ozan Cemal, additional, Inanc, Murat, additional, Inanc, Nevsun, additional, Koca, Suleyman Serdar, additional, Kucuksahin, Orhan, additional, Ozgen, Metin, additional, Sari, Alper, additional, Sahin, Ali, additional, Senel, Soner, additional, Tufan, Abdurrahman, additional, Ugurlu, Serdal, additional, Yargucu Zihni, Figen, additional, Yolbas, Servet, additional, and Hamuryudan, Vedat, additional

Published
2023
Full Text
View/download PDF

30. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

Author

Karadag, Omer, primary, Dalkilic, Ediz, additional, Ayan, Gizem, additional, Kucuksahin, Orhan, additional, Kasifoglu, Timucin, additional, Yilmaz, Neslihan, additional, Koca, Suleyman Serdar, additional, Yazisiz, Veli, additional, Erten, Pinar Talu, additional, Sayarlioglu, Mehmet, additional, Terzioglu, Mustafa Ender, additional, Erten, Sukran, additional, and Kalyoncu, Umut, additional

Published
2021
Full Text
View/download PDF

33. Methodology of a new inflammatory arthritis registry: TReasure

Author

Tufan, Muge Aydin, Kalyoncu, Umut, Tascilar, Etem Koray, Ertenli, Ali Ihsan, Dalkilic, Huseyin Ediz, Bes, Cemal, Kucuksahin, Orhan, Kasifoglu, Timucin, Alpay Kanitez, Nilufer, Emmungil, Hakan, Kimyon, Gezmis, Yasar Bilge, Nafize Sule, Akar, Servet, Atagunduz, Mehmet Pamir, Koca, Suleyman Serdar, Ates, Askin, Yazisiz, Veli, Terzioglu, Ender, Ersozlu, Emine Duygu, Cinar, Muhammet, Mercan, Ridvan, Sahin, Ali, Erten, Sukran, Pehlivan, Yavuz, Yilmaz, Sedat, Kelesoglu Dincer, Ayse Bahar, Gercik, Onay, Coskun, Belkis Nihan, Yagiz, Burcu, Kaymaz Tahra, Sema, Aksoy, Aysun, Karadag, Omer, Kilic, Levent, Kiraz, Sedat, [Kalyoncu, Umut -- Ertenli, Ali Ihsan -- Karadag, Omer -- Kilic, Levent -- Kiraz, Sedat] Hacettepe Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Tascilar, Etem Koray] Okmeydani Training & Res Hosp, Rheumatol Clin, Istanbul, Turkey -- [Dalkilic, Huseyin Ediz -- Pehlivan, Yavuz -- Coskun, Belkis Nihan -- Yagiz, Burcu] Uludag Univ, Fac Med, Dept Internal Med, Div Rheumatol, Bursa, Turkey -- [Bes, Cemal -- Alpay Kanitez, Nilufer] Rheumatol Clin, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Istanbul, Turkey -- [Kucuksahin, Orhan] Istinye Univ, Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey -- [Kasifoglu, Timucin -- Yasar Bilge, Nazife Sule] Eskisehir Osmangazi Univ, Fac Med, Dept Internal Med, Div Rheumatol, Eskisehir, Turkey -- [Emmungil, Hakan] Trakya Univ, Fac Med, Dept Internal Med, Div Rheumatol, Edirne, Turkey -- [Kimyon, Gezmis] Mustafa Kemal Univ, Fac Med, Dept Internal Med, Div Rheumatol, Antakya, Turkey -- [Akar, Servet -- Gercik, Onay] Izmir Katip Celebi Univ, Fac Med, Dept Internal Med, Div Rheumatol, Izmir, Turkey -- [Atagunduz, Mehmet Pamir -- Kaymaz Tahra, Sema -- Aksoy, Aysun] Marmara Univ, Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey -- [Koca, Suleyman Serdar] Firat Univ, Fac Med, Dept Internal Med, Div Rheumatol, Elazig, Turkey -- [Ates, Askin] Ankara Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Yazisiz, Veli -- Terzioglu, Ender] Akdeniz Univ, Fac Med, Dept Internal Med, Div Rheumatol, Antalya, Turkey -- [Ersozlu, Emine Duygu] Adana Numune Training & Res Hosp, Unit Rheumatol, Adana, Turkey -- [Tufan, Muge Aydin] Baskent Univ, Unit Rheumatol, Adana Hosp, Adana, Turkey -- [Cinar, Muhammet -- Yilmaz, Sedat] Univ Hlth Sci, Gulhane Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey -- [Mercan, Ridvan] Namik Kemal Univ, Fac Med, Dept Internal Med, Div Rheumatol, Tekirdag, Turkey -- [Sahin, Ali] Cumhuriyet Univ, Fac Med, Dept Internal Med, Div Rheumatol, Sivas, Turkey -- [Erten, SUkran] Yildirim Beyazit Univ, Fac Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey, TASCILAR, Koray -- 0000-0002-8109-826X, Kaymaz-Tahra, Sema -- 0000-0001-5706-4943, Kalyoncu, Umut, Tascilar, Etem Koray, Ertenli, Ali Ihsan, Dalkilic, Huseyin Ediz, Bes, Cemal, Kucuksahin, Orhan, Kasifoglu, Timucin, Alpay Kanitez, Nilufer, Emmungil, Hakan, Kimyon, Gezmis, Yasar Bilge, Nazife Sule, Akar, Servet, Atagunduz, Mehmet Pamir, Koca, Suleyman Serdar, Ates, Askin, Yazisiz, Veli, Terzioglu, Ender, Ersozlu, Emine Duygu, Tufan, Muge Aydin, Cinar, Muhammet, Mercan, Ridvan, Sahin, Ali, Erten, SUkran, Pehlivan, Yavuz, Yilmaz, Sedat, Kelesoglu Dincer, Ayse Bahar, Gercik, Onay, Coskun, Belkis Nihan, Yagiz, Burcu, Kaymaz Tahra, Sema, Aksoy, Aysun, Karadag, Omer, Kilic, Levent, Kiraz, Sedat, İç Hastalıkları, İstinye Üniversitesi, Hastane, and Ege Üniversitesi

Subjects
Male, 0301 basic medicine, Turkey, Cross-sectional study, Inflammatory arthritis, NECROSIS FACTOR THERAPY, Datasets as Topic, Biologics Register, CLINICAL HISTORY, registry, DISEASE-ACTIVITY, Arthritis, Rheumatoid, Unique identifier, 0302 clinical medicine, Disease-Activity, Psoriatic-Arthritis, Health care, disease-modifying antirheumatic drugs, Necrosis Factor Therapy, Prospective Studies, Registries, Cerrahi, Rheumatoid-Arthritis, Clinical History, ANKYLOSING-SPONDYLITIS, General Medicine, Middle Aged, spondyloarthritis, BACK-PAIN, Antirheumatic Agents, Cohort, Society Classification Criteria, Female, Back-Pain, Treasure, medicine.medical_specialty, TReasure, Drug Industry, DIAGNOSTIC-CRITERIA, Ankylosing-Spondylitis, 03 medical and health sciences, Spondylarthritis, medicine, Humans, Rheumatoid arthritis, Diagnostic-Criteria, Aged, Retrospective Studies, business.industry, Retrospective cohort study, medicine.disease, RHEUMATOID-ARTHRITIS, Cross-Sectional Studies, 030104 developmental biology, Rheumatoid arthritis,spondyloarthritis,disease-modifying antirheumatic drugs,registry,TReasure, Family medicine, PSORIATIC-ARTHRITIS, BIOLOGICS REGISTER, 030221 ophthalmology & optometry, SOCIETY CLASSIFICATION CRITERIA, Observational study, Health Facilities, Societies, business
Abstract

WOS: 000441766000023, PubMed ID: 30119164, Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.

Published
2018

40. COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Author

Esatoglu, Sinem Nihal, primary, Tascilar, Koray, additional, Babaoglu, Hakan, additional, Bes, Cemal, additional, Yurttas, Berna, additional, Akar, Servet, additional, Pehlivan, Ozlem, additional, Akleylek, Cansu, additional, Tecer, Duygu, additional, Seyahi, Emire, additional, Yuce-Inel, Tuba, additional, Alpay-Kanitez, Nilufer, additional, Bodakci, Erdal, additional, Tekgoz, Emre, additional, Colak, Seda, additional, Bolek, Ertugrul Cagri, additional, Koca, Suleyman Serdar, additional, Kalyoncu, Umut, additional, Icacan, Ozan Cemal, additional, Ugurlu, Serdal, additional, Oz, Hande Ece, additional, Hamuryudan, Vedat, additional, and Hatemi, Gulen, additional

Published
2020
Full Text
View/download PDF

41. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis

Author

Michelsen, Brigitte, primary, Ørnbjerg, Lykke Midtbøll, additional, Kvien, Tore K, additional, Pavelka, Karel, additional, Nissen, Michael J, additional, Nordström, Dan, additional, Santos, Maria José, additional, Koca, Suleyman Serdar, additional, Askling, Johan, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Codreanu, Catalin, additional, Loft, Anne Gitte, additional, Kristianslund, Eirik Klami, additional, Mann, Herman F, additional, Ciurea, Adrian, additional, Eklund, Kari K, additional, Vieira-Sousa, Elsa, additional, Yazici, Ayten, additional, Jacobsson, Lennart, additional, Tomšič, Matija, additional, Löve, Thorvardur Jón, additional, Ionescu, Ruxandra, additional, van der Horst-Bruinsma, I E, additional, Iannone, Florenzo, additional, Pombo-Suarez, Manuel, additional, Jones, Gareth T, additional, Hyldstrup, Lise Hejl, additional, Krogh, Niels Steen, additional, Hetland, Merete Lund, additional, and Østergaard, Mikkel, additional

Published
2020
Full Text
View/download PDF

42. Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naive or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study

Author

Direskeneli, Haner, Karadag, Omer, Ates, Askin, Tufan, Abdurrahman, Inanc, Nevsun, Koca, Suleyman Serdar, Cetin, Gozde Yildirim, Akar, Servet, Cinar, Muhammet, Yilmaz, Sedat, Yilmaz, Neslihan, Dalkilic, Ediz, Bes, Cemal, Ozbalkan, Zeynep, Yilmazer, Baris, ALI SAHIN, Ersozlu, Emine Duygu, Tezcan, Mehmet Engin, Sen, Nesrin, Keser, Gokhan, Tansoker, Ilkan, Hacibedel, Fatma Basak, Helvacioglu, Kerem, Gunay, Levent Mert, [Direskeneli, Haner -- Inanc, Nevsun] Marmara Univ, Sch Med, Rheumatol, Istanbul, Turkey -- [Karadag, Omer] Hacettepe Univ, Fac Med, Ankara, Turkey -- [Ates, Askin] Ankara Univ, Div Rheumatol, Dept Internal Med, Sch Med, Ankara, Turkey -- [Tufan, Abdurrahman] Gazi Univ, Internal Med Rheumatol, Fac Med, Ankara, Turkey -- [Koca, Suleyman Serdar] Firat Univ, Rheumatol, Fac Med, Elazig, Turkey -- [Cetin, Gozde Yildirim] Sutcu Imam Univ, Sch Med, Div Rheumatol, Dept Internal Med, Kahramanmaras, Turkey -- [Akar, Servet] Izmir Katip Celebi Univ, Dept Rheumatol, Fac Med, Izmir, Turkey -- [Cinar, Muhammet -- Yilmaz, Sedat] Gulhane Training & Res Hosp, Div Rheumatol, Ankara, Turkey -- [Yilmaz, Neslihan] Bilim Univ, Dept Rheumatol, Fac Med, Istanbul, Turkey -- [Dalkilic, Ediz] Uludag Univ, Rheumatol, Fac Med, Bursa, Turkey -- [Bes, Cemal] Hlth Sci Univ Dr Sadi Konuk Training & Res Hosp, Dept Rheumatol, Istanbul, Turkey -- [Ozbalkan, Zeynep] Ankara Numune Training & Res Hosp, Div Rheumatol, Ankara, Turkey -- [Yilmazer, Baris] Canakkale Onsekiz Mart Univ, Fac Med, Div Rheumatol, Internal Med, Canakkale, Turkey -- [Sahin, Ali] Cumhuriyet Univ, Dept Rheumatol, Fac Med, Sivas, Turkey -- [Ersozlu, Emine Duygu] Minist Hlth, Div Rheumatol, Adana City Hosp, Adana, Turkey -- [Tezcan, Mehmet Engin -- Sen, Nesrin] Minist Hlth, Istanbul Kartal Training & Res Hosp, Rheumatol Div, Istanbul, Turkey -- [Keser, Gokhan] Ege Univ, Rheumatol, Fac Med, Izmir, Turkey -- [Tansoker, Ilkan -- Gunay, Levent Mert] Pfizer, Med Dept, Istanbul, Turkey -- [Hacibedel, Fatma Basak -- Helvacioglu, Kerem] Pfizer, Hlth Econ & Outcomes Res Dept, Istanbul, Turkey, and Tezcan, Mehmet Engin -- 0000-0002-1753-4936

Abstract

WOS: 000447268901146, …

Published
2018

43. The 6-month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib.

Author

Karatas, Ahmet, Gur, Mustafa, Oz, Burak, Sagir, Rabia Piskin, Hohluoglu, Abdulvahap, Gozel, Nevzat, and Koca, Suleyman Serdar

Subjects
RHEUMATOID arthritis, DRUG utilization, JANUS kinases, AUTOIMMUNE diseases, KINASE inhibitors
Abstract

Aim: Rheumatoid arthritis (RA) is a progressive, inflammatory, autoimmune disease that particularly affects the joints. Tofacitinib is the first oral Janus kinase inhibitor approved for RA treatment. We aimed to analyze the 6-month drug survival rate and factors affecting the discontinuation of tofacitinib in RA patients. Materials and Methods: Age, gender, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) levels, whether to continue treatment tofacitinib, if treatment is not continued what treatment is applied, use of biological agent before tofacitinib treatment were retrospectively recorded from the patient data. Results: 30 RA patients included in the study (29 female, 1 male) with a mean age of 50.5 ± 11.3 years. At the 6th month of treatment of tofacitinib, the drug survival rates were 50%. There was no significant difference between CCP positive and negative patients as well as between RF positive and negative patients in terms of drug survival rates (p = 0.92 and p = 0.90, respectively). The drug survival rates were alike in tofacitinib monotherapy and combined therapy of tofacitinib with any conventional DMARD (p = 0.36). The tofacitinib survival rates were similar in biologically naïve patients and in patients who had received at least one previous biological DMARD (p = 0.70). Conclusion: Half of the RA patients receiving tofacitinib treatment continue their treatment at the 6th month. The drug survival rate was not associated with co-treatment with conventional DMARD, auto-antibody positivities, and previously used biological DMARD therapy. These findings support that tofacitinib shows similar efficacy when used as combined or monotherapy, in seronegative or seropositive patients, and in biologic resistant or naive patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis

Author

Yagiz, Burcu, Coskun, Belkis Nihan, Kiraz, Sedat, Ertenli, Ihsan, Kucuksahin, Orhan, Dalkilic, Ediz, Bes, Cemal, Kanitez, Nilufer Alpay, Kasifoglu, Timucin, Emmungil, Hakan, Atagunduz, Pamir, Koca, Suleyman Serdar, Cinar, Muhammet, Ates, Askin, Akar, Servet, Gercik, Onay, Bakirli, Duygu Ersozlu, Yazisiz, Veli, Kimyon, Gezmis, Bilge, Nazife Sule Yasar, Muge Aydin Tufan, Mercan, Ridvan, Oz, Burak, Akar, Zeynel Abidin, Karadag, Omer, Kelesoglu, Bahar, Yilmaz, Sedat, Turan, Sezin, Pehlivan, Yavuz, Terzioglu, Ender, Kilic, Levent, Erten, Sukran, Tascilar, Koray, and Kalyoncu, Umut

Published
2018

47. COVID-19 Among Patients With Inflammatory Rheumatic Diseases.

Author

Esatoglu, Sinem Nihal, Tascilar, Koray, Babaoğlu, Hakan, Bes, Cemal, Yurttas, Berna, Akar, Servet, Pehlivan, Ozlem, Akleylek, Cansu, Tecer, Duygu, Seyahi, Emire, Yuce-Inel, Tuba, Alpay-Kanitez, Nilufer, Bodakci, Erdal, Tekgoz, Emre, Colak, Seda, Bolek, Ertugrul Cagri, Koca, Suleyman Serdar, Kalyoncu, Umut, Icacan, Ozan Cemal, and Ugurlu, Serdal

Subjects
COVID-19, SARS-CoV-2, RHEUMATISM, REPORTING of diseases, LOGISTIC regression analysis
Abstract

Background: The course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used for IRDs, that may affect innate immune responses. Objective: In this cohort study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among Turkish patients with IRDs. Methods: Between April and June, 2020, 167 adult IRD patients with COVID-19 were registered from 31 centers in 14 cities in Turkey. Disease outcome was classified in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive care unit (ICU) admission or death. Multivariable ordinal logistic regression analysis was conducted to determine variables associated with a worse outcome. Results: 165 patients (mean age: 50 ± 15.6 years, 58.2% female) were included. Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses and outcome were inconclusive. Conclusions: Among IRD patients with COVID-19, comorbidities and glucocorticoid use were associated with a worse outcome, while biologic DMARDs do not seem to be associated with a worse outcome. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Epigallocatechin 3‐gallate attenuates arthritis by regulating Nrf2, HO‐1, and cytokine levels in an experimental arthritis model.

Author

Karatas, Ahmet, Dagli, Adile Ferda, Orhan, Cemal, Gencoglu, Hasan, Ozgen, Metin, Sahin, Nurhan, Sahin, Kazim, and Koca, Suleyman Serdar

Subjects
EXPERIMENTAL arthritis, COLLAGEN-induced arthritis, ARTHRITIS, RHEUMATOID arthritis, SUPEROXIDE dismutase, CATALASE, GLUTATHIONE peroxidase
Abstract

Epigallocatechin 3‐gallate (EGCG) is a polyphenol that has been shown to have antioxidant and anti‐inflammatory effects. In this study, collagen‐induced arthritis (CIA) model, in Wistar albino rats, was used to elucidate the effect of EGCG on pathogenetic pathways in inflammatory arthritis. The levels of serum TNF‐α, IL‐17, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx); the expression levels of tissue heme oxygenase‐1 (HO‐1) and nuclear factor erythroid 2‐related factor 2 (Nrf2); histopathologically, perisynovial inflammation and cartilage‐bone destruction were examined. In the sham group, serum TNF‐α, IL‐17, and MDA levels increased, while SOD, CAT, GPx levels, and the expressions of Nrf2 and HO‐1 decreased. On the other hand, in the EGCG administered groups, serum TNF‐α, IL‐17, and MDA levels improved, while SOD, CAT, GPx levels and the expressions of Nrf2 and HO‐1 increased. Moreover, histopathological analysis has shown that perisynovial inflammation and cartilage‐bone destruction decreased in the EGCG administered groups. These results suggest that EGCG has an antiarthritic effect by regulating the oxidative‐antioxidant balance and cytokine levels in the CIA model, which is a surrogate experimental model of rheumatoid arthritis. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results